Evidence map›Paper›PMID 25255445›Full record

ArticlePLoS genetics2014

Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.

Alessio Iannetti, Adeline C Ledoux, Susan J Tudhope, Hélène Sellier, Bo Zhao, Sophia Mowla, Adam Moore, Holger Hummerich, Benjamin E Gewurz, Simon J Cockell and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. TPH1 and 5-HTCancers · 2021
    Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Alessio IannettiInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Adeline C LedouxInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Susan J TudhopeNorthern Institute for Cancer Research, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Hélène SellierInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Bo ZhaoDivision of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Sophia MowlaDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
Adam MooreInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Holger HummerichDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
Benjamin E GewurzDivision of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Simon J CockellBioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Parmjit S JatDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
Elaine WillmoreNorthern Institute for Cancer Research, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Neil D PerkinsInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Newcastle University · GBUniversity College London · GBBrigham and Women's Hospital · US

Funding

Genetic and Proteomic Analysis of Epstein-Barr Virus LMP1 Activation of NF-kBK08CA140780 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2010 to 2014
$900k
Cancer Research UK C1443/A12750Cancer Research UK C1443/A9215NCI NIH HHS K08 CA140780NCI NIH HHS R01 CA12850Wellcome TrustWellcome Trust 094409Worldwide Cancer Research 13-1150
6 · The paper itself

Abstract

There are two major pathways leading to induction of NF-κB subunits. The classical (or canonical) pathway typically leads to the induction of RelA or c-Rel containing complexes, and involves the degradation of IκBα in a manner dependent on IκB kinase (IKK) β and the IKK regulatory subunit NEMO. The alternative (or non-canonical) pathway, involves the inducible processing of p100 to p52, leading to the induction of NF-κB2(p52)/RelB containing complexes, and is dependent on IKKα and NF-κB inducing kinase (NIK). Here we demonstrate that in primary human fibroblasts, the alternative NF-κB pathway subunits NF-κB2 and RelB have multiple, but distinct, effects on the expression of key regulators of the cell cycle, reactive oxygen species (ROS) generation and protein stability. Specifically, following siRNA knockdown, quantitative PCR, western blot analyses and chromatin immunoprecipitation (ChIP) show that NF-κB2 regulates the expression of CDK4 and CDK6, while RelB, through the regulation of genes such as PSMA5 and ANAPC1, regulates the stability of p21WAF1 and the tumour suppressor p53. These combine to regulate the activity of the retinoblastoma protein, Rb, leading to induction of polycomb protein EZH2 expression. Moreover, our ChIP analysis demonstrates that EZH2 is also a direct NF-κB target gene. Microarray analysis revealed that in fibroblasts, EZH2 antagonizes a subset of p53 target genes previously associated with the senescent cell phenotype, including DEK and RacGAP1. We show that this pathway provides the major route of crosstalk between the alternative NF-κB pathway and p53, a consequence of which is to suppress cell senescence. Importantly, we find that activation of NF-κB also induces EZH2 expression in CD40L stimulated cells from Chronic Lymphocytic Leukemia patients. We therefore propose that this pathway provides a mechanism through which microenvironment induced NF-κB can inhibit tumor suppressor function and promote tumorigenesis.

Indexed as

Signal TransductionCD40 LigandCellular SenescenceCluster AnalysisEnhancer of Zeste Homolog 2 ProteinEnzyme ActivationFibroblastsGene Expression ProfilingGene Expression RegulationHumansLeukemia, Lymphocytic, Chronic, B-CellModels, BiologicalNF-kappa BNF-kappa B p52 SubunitPolycomb Repressive Complex 2Protein BindingCD40 LigandEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanNF-kappa BNF-kappa B p52 SubunitPolycomb Repressive Complex 2Reactive Oxygen SpeciesRetinoblastoma ProteinTranscription Factor RelBTumor Suppressor Protein p53

Identifiers

PMID25255445
PMCPMC4177746
OpenAlexW1990232520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.